## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

l	OND ALLINO	OIVID AFFINOVAL										
	OMB Number:	3235-0287										
	Estimated average burden											
l	houre por roeponeo:	0.5										

OMB ADDDOMAI

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							(,			.,,								
1. Name and Address of Reporting Person*  DOTSON JERROLD DUANE						2. Issuer Name <b>and</b> Ticker or Trading Symbol  VistaGen Therapeutics, Inc. [ VSTA ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  V Officer (give title Other (specify					
(Last) (First) (Middle) C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 11/11/2015								X Officer (give title Other (specify below)  CFO AND SECRETARY					
(Street) SOUTH SAN FRANCISCO CA			94080		4. If Ar	nendmen	t, Date of	f Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																		
			Table I - Non-	Deriva	ative	Securit	ies Acc	quired,	Disp	osed of,	or Bene	ficially	Owned					
Date					Saction 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.			s Acquired ( If (D) (Instr. :	Acquired (A) or (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		Direct II Indirect E tr. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									v	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				(msu. 4)	
			Table II - D (e							sed of, o onvertible			wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. r) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin	re es ally ig	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		Reported Transact (Instr. 4)	action(s)			
Warrant for Common Stock	\$12.8	11/11/2015		D <sup>(1)</sup>			10,000	04/01/2015 <sup>(1)</sup>		03/03/2023	Common Stock	10,000	\$0 <sup>(1)</sup>			D		
Warrant for Common Stock	<b>\$</b> 7	11/11/2015		A <sup>(1)</sup>		10,000		04/01/20	)15 <sup>(1)</sup>	03/03/2023	Common Stock	10,000	\$0 <sup>(1)</sup>	10,000		D		
Warrant for Common Stock	\$10	11/11/2015		D <sup>(2)</sup>			5,000	(3)(4	4)	03/19/2019	Common Stock	5,000	\$0 <sup>(4)</sup>	0		D		
Warrant for Common Stock	\$7	11/11/2015		A <sup>(4)</sup>		5,000		(3)(4	1)	03/19/2019	Common Stock	5,000	\$0 <sup>(4)</sup>	5,00	00	D		
Warrant for Common Stock	\$10	11/11/2015		D <sup>(5)</sup>			50,000	01/11/20	)15 <sup>(5)</sup>	01/11/2020	Common Stock	50,000	\$0 <sup>(5)</sup>	0		D		
Warrant for Common Stock	\$7	11/11/2015		A <sup>(5)</sup>		50,000		01/11/20	)15 <sup>(5)</sup>	01/11/2020	Common Stock	50,000	\$0 <sup>(5)</sup>	50,0	00	D		
Warrant for Common Stock	\$9.25	11/11/2015		D <sup>(6)</sup>			100,000	09/02/20	)15 <sup>(6)</sup>	09/02/2020	Common Stock	100,000	\$0 <sup>(6)</sup>	0		D		
Warrant for Common	\$7	11/11/2015		A <sup>(6)</sup>		100,000		09/02/20	)15 <sup>(6)</sup>	09/02/2020	Common Stock	100,000	\$0 <sup>(6)</sup>	100,0	000	D		

## **Explanation of Responses:**

- 1. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the old warrant and the grant of a replacement warrant. The warrant was originally granted on March 3, 2013.
- 2. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the old warrant and the grant of a replacement warrant. The warrant was originally granted on March 19, 2014.
- 3. Subject to the Reporting Person's continuous service, and as incentive to continue employment and build shareholder value, the Warrant will vest according to the following schedule: 50% of the total number of shares on April 1, 2014 (the "Vesting Start Date"); 25% of the total number of shares on the one year anniversary of the Vesting Start Date; and 25% of the total number of shares on the two year anniversary of the Vesting Start Date; provided, however, that the Warrant shall vest in full upon a change in control of the Company, or upon the consummation by the Company and a third-party of a license or sale transaction involving at least one (1) new drug rescue variant developed by the Company.
- 4. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the old warrant and the grant of a replacement warrant. The warrant was originally granted on March 19, 2014.
- 5. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the old warrant and the grant of a replacement warrant. The warrant was originally granted on January 11, 2015.
- 6. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the old warrant and the grant of a replacement warrant. The warrant was originally granted on September 2, 2015.

11/13/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.